Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2012
05/29/2012US8188004 Organic herbicide
05/29/2012US8187672 Residual solvent extraction method and microparticles produced thereby
05/29/2012US8187642 Modified pectins, compositions and methods related thereto
05/29/2012US8187634 Process for the preparation of sevelamer hydrochloride and formulation thereof
05/29/2012US8187632 Sustained-release preparations of quinolone antibiotics
05/29/2012US8187631 Direct compression polymer tablet core
05/29/2012US8187630 Extended release oral dosage composition
05/29/2012US8187629 Non-lamellar compositions of DOPE and P80
05/29/2012US8187624 Compositions for taking dietary fibers
05/29/2012US8187620 Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents
05/29/2012US8187615 Non-aqueous compositions for oral delivery of insoluble bioactive agents
05/29/2012US8187597 Combination therapy for the treatment of ocular neovascular disorders
05/29/2012US8187590 Probiotic, lactic acid-producing bacteria and uses thereof
05/29/2012US8187583 Oil-in-water emulsions
05/29/2012US8187278 Photodynamic cellular and acellular organism eradication utilizing a photosensitive material and benzalkonium chloride
05/29/2012CA2687927C Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
05/29/2012CA2684582C N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy} benzamidine 2 ethansulfonic acid salt, process for the preparation thereof and pharmaceutical compositioncomprising the same
05/29/2012CA2682849C Sulfonamides and pharmaceutical compositions thereof
05/29/2012CA2649022C Cocrystal of c-glycoside derivative and l-proline
05/29/2012CA2594349C Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc
05/29/2012CA2583876C A transmucosal veterinary composition comprising detomidine
05/29/2012CA2582556C Formulations and methods for treating amyloidosis
05/29/2012CA2558944C Enhancement of activity and/or duration of action of soft anti-inflammatory steroids for topical or other local application
05/29/2012CA2557910C Methods of reducing aggregation of il-1ra
05/29/2012CA2555624C Thioamide compounds or salts thereof and cytokine production inhibitors containing the same
05/29/2012CA2554751C Anti-inflammatory analgesic for external use
05/29/2012CA2554730C Oral care compositions comprising increased bioavailable levels of quaternary ammonium antimicrobials
05/29/2012CA2551501C Tolterodine, compositions and uses thereof, and preparation of the same
05/29/2012CA2542140C Crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
05/29/2012CA2541109C Composition for the activation of the immune system
05/29/2012CA2537095C Combinations of a pyrimidine containing nnrti with rt inhibitors
05/29/2012CA2534241C Compositions and methods for treating, preventing and/or ameliorating cancers, the onset of cancers or the symptoms of cancers
05/29/2012CA2531210C Imidazole derivatives and their use in the treatment of mglur5 receptor mediated disorders
05/29/2012CA2529561C Methanesulfonic acid salt of pyrazolopyrimidine compound, crystal thereof, and process for producing the same
05/29/2012CA2523196C Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals
05/29/2012CA2521425C Substituted phenoxy-acetic acids
05/29/2012CA2520522C Cladribine formulations for improved oral and transmucosal delivery
05/29/2012CA2516667C Treatment using dantrolene
05/29/2012CA2516022C Model for studying the role of genes in tumor resistance to chemotherapy
05/29/2012CA2512487C Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
05/29/2012CA2502219C A process for producing an amorphous isomer of lansoprazole
05/29/2012CA2496585C Novel 1,4-diazabicycloalkane derivatives, their preparation and use
05/29/2012CA2496127C Piperidinyl compounds that selectively bind integrins
05/29/2012CA2495350C Use of lck inhibitor for treatment of immunologic diseases
05/29/2012CA2495260C Resolvins: biotemplates for novel therapeutic interventions
05/29/2012CA2490972C Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
05/29/2012CA2487846C Method, composition and kit for antigenic binding of norwalk-like viruses
05/29/2012CA2483998C Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredient
05/29/2012CA2482499C Aerosol containing a particulate active substance
05/29/2012CA2481036C (3z)-(3-(3-hydro-isobenzofuran-1-ylidene)-1,3-dihydro-2h-indol-2-ones as kinase inhibitors
05/29/2012CA2463966C Pyrazolyl-substituted heterocycles and their use as phytosanitary products
05/29/2012CA2458611C Aminobenzophenones as interleukin 1-beta and tumour necrosis factor-alpha inhibitors
05/29/2012CA2455403C Synthetic or natural peptides binding protein phosphatase 2a, identification method and uses
05/29/2012CA2446738C Abuse-resistant opioid dosage form
05/29/2012CA2442168C N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
05/29/2012CA2441597C Elongated and multiple spacers in activatible prodrugs
05/29/2012CA2426393C Crystalline forms of venlafaxine hydrochloride
05/29/2012CA2322157C Synthesis of epothilones, intermediates thereto and analogues thereof
05/29/2012CA2318731C Ppar-gamma modulators
05/29/2012CA2269118C Epothilone c, d, e and f, production process, and their use as cytostatic as well as phytosanitary agents
05/29/2012CA2268258C Single-chain multiple antigen-binding molecule, its preparation and use
05/29/2012CA2220777C Novel heterocycles as inhibitors of leucocyte adhesion and as vla-4 antagonists
05/26/2012CA2723561A1 Method of reducing side effects of non-steroidal anti-inflammatory drugs
05/24/2012WO2012068589A2 Modulators of methyl modifying enzymes, compositions and uses thereof
05/24/2012WO2012068560A2 4-quinolinemethanols as anti-malarial agents
05/24/2012WO2012068553A2 Methods of diagnosing and treating neurodegenerative diseases
05/24/2012WO2012068552A1 Methods for improving blood glucose control
05/24/2012WO2012068546A1 Heterocycle amines and uses thereof
05/24/2012WO2012068539A1 Use and composition of quercetin-3'-o-sulfate for therapeutic treatment
05/24/2012WO2012068535A1 Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
05/24/2012WO2012068529A2 Cannabinoid receptor antagonists-inverse agonists useful for treating metabolic disorders, including obesity and diabetes
05/24/2012WO2012068516A2 Low dose cannabinoid medicaments
05/24/2012WO2012068512A1 3-deutero-pomalidomide
05/24/2012WO2012068491A1 Preselection of subjects for therapeutic treatment with elesclomol based on hypoxic status
05/24/2012WO2012068487A1 Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status
05/24/2012WO2012068483A1 Preselection of subjects for therapeutic treatment based on hypoxic status
05/24/2012WO2012068470A2 Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
05/24/2012WO2012068468A1 Method of treatment with braf inhibitor
05/24/2012WO2012068456A2 Compositions and methods for treating obesity
05/24/2012WO2012068454A2 Nrf2 deficiency influences susceptibility to steroid resistance via hdac2 reduction
05/24/2012WO2012068450A1 Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
05/24/2012WO2012068435A1 Method for treating breast cancer and ovarian cancer
05/24/2012WO2012068412A2 Method and compositions for treatment of stat3-responsive cancers and/or renal cancer
05/24/2012WO2012068410A1 Methods for treating chronic or unresolvable pain and/or increasing the pain threshold in a subject and pharmaceutical compositions for use therein
05/24/2012WO2012068406A2 Use of hematopoietic growth factor mimetics
05/24/2012WO2012068390A1 INHIBITORS OF FOOT AND MOUTH DISEASE VIRUS TARGETING THE RNA-DEPENDENT POLYMERASE ACTIVITY OF 3Dpol
05/24/2012WO2012068381A2 Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6
05/24/2012WO2012068380A2 Methods and compositions for modulating pd1
05/24/2012WO2012068366A2 Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus
05/24/2012WO2012068355A2 Treating aortic aneurysm by modulating toll-like receptors
05/24/2012WO2012068343A1 Quinoline derivatives as pik3 inhibitors
05/24/2012WO2012068340A2 Antagonat compositions and methods of use
05/24/2012WO2012068339A2 Methods of treating cancer
05/24/2012WO2012068319A2 Method of treating hematological cancers
05/24/2012WO2012068299A2 Cbp/catenin antagonists for enhancing asymmetric division of somatic stem cells
05/24/2012WO2012068274A1 Treatment of type ii diabetes and diabets-associated diseases with safe chemical mitochondrial uncouplers
05/24/2012WO2012068251A2 Agonists that enhance binding of integrin-expressing cells to integrin receptors
05/24/2012WO2012068234A2 Antiviral compounds
05/24/2012WO2012068211A1 Tricyclic inhibitors of pro-matrix metalloproteinase activation
05/24/2012WO2012068210A1 Pyridyl-thiazolyl inhibitors of pro-matrix metalloproteinase activation
1 ... 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 1224 1225 1226 1227 1228 1229 1230 ... 7860